surmount-1 tirzepatide trial obesity without diabetes For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The SURMOUNT-1 Trial - Cardionerds Twitter

Next Steps: today, to see if Ipamorelin is right for you

Monitoring blood sugar, kidney function, and hydration status becomes important if you have diabetes or prediabetes, since tirzepatide's glucose-lowering effects may require adjustment of concurrent diabetes medications to prevent hypoglycemia

How well they work can vary from person to person, so treatment should be individualized with guidance from a healthcare provider

As little as 5% of body weight

Fact: It is most effective when combined with a total plan which consists of diet, exercise, and behavior change

This option is ideal for those with sensitivity or as a starting point before advancing to standard dosing